Hoth Therapeutics Future Growth

Future criteria checks 0/6

Hoth Therapeutics's earnings are forecast to decline at 34.3% per annum. EPS is expected to grow by 32.3% per annum.

Key information

-34.3%

Earnings growth rate

32.3%

EPS growth rate

Pharmaceuticals earnings growth	23.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	05 Apr 2024

Recent future growth updates

Recent updates

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Sep 20

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Jun 29

Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers

May 03

Hoth provides pipeline and regulatory timeline update

Feb 02

FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%

Jan 13

Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer

Jan 11

Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%

Jan 04

Hoth therapeutics signs production agreement for HT-001, Shares up 75%

Dec 31

Companies Like Hoth Therapeutics (NASDAQ:HOTH) Could Be Quite Risky

Dec 02

Hoth Therapeutics shows encouraging preclinical action in autoimmune skin disorder

Nov 03

Earnings and Revenue Growth Forecasts

NasdaqCM:HOTH - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	N/A	N/A	N/A	1
12/31/2025	N/A	-16	N/A	N/A	1
12/31/2024	N/A	-12	N/A	-12	1
12/31/2023	N/A	-8	-8	-8	N/A
9/30/2023	N/A	-10	-8	-8	N/A
6/30/2023	N/A	-10	-9	-9	N/A
3/31/2023	N/A	-11	-9	-9	N/A
12/31/2022	N/A	-11	-9	-9	N/A
9/30/2022	N/A	-11	-11	-11	N/A
6/30/2022	N/A	-12	-11	-11	N/A
3/31/2022	N/A	-13	-12	-12	N/A
12/31/2021	N/A	-14	-12	-12	N/A
9/30/2021	N/A	-12	-9	-9	N/A
6/30/2021	N/A	-10	-8	-8	N/A
3/31/2021	N/A	-10	-7	-7	N/A
12/31/2020	N/A	-7	-6	-6	N/A
9/30/2020	N/A	-10	-7	-7	N/A
6/30/2020	N/A	-10	-7	-7	N/A
3/31/2020	N/A	-9	-6	-6	N/A
12/31/2019	N/A	-8	-5	-5	N/A
9/30/2019	N/A	-4	-4	-4	N/A
6/30/2019	N/A	-3	-3	-3	N/A
3/31/2019	N/A	-3	-3	-3	N/A
12/31/2018	N/A	-2	-2	-2	N/A
9/30/2018	N/A	-3	-2	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HOTH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HOTH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HOTH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if HOTH's revenue is forecast to grow faster than the US market.

High Growth Revenue: HOTH is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if HOTH's Return on Equity is forecast to be high in 3 years time

Hoth Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 50% to US$9.50

Price target decreased to US$19.00

Price target decreased to US$3.00

Price target decreased to US$3.50

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Recent updates

Hoth Therapeutics, Inc. Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

Hoth Therapeutics Receives FDA Approval to Expand HT-001 Clinical Trial to Treat Severely III Patients

Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial for Cancer Patients of HT-001 At University of Miami

Hoth Therapeutics Announces Successfully Completed Manufacturing of its Cancer Fighting HT-KIT for Ind-Enabling Studies

Hoth Therapeutics, Inc. Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

Price target decreased by 50% to US$9.50

Hoth Therapeutics, Inc. Doses First Patient in its Phase 2a Clinical Trial of HT-001 for Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors

Hoth Therapeutics, Inc. Receives Protocol Approval for HT-001 Cancer Therapeutic

Hoth Therapeutics Announces Irb Approval for Fda Cleared First-In-Human Clinical Trial of Ht-001 At Second Clinical Site

New major risk - Share price stability

Hoth Therapeutics, Inc., Annual General Meeting, Aug 18, 2023

Algorithm Sciences, Inc. cancelled the acquisition of Hoth Therapeutics, Inc. (NasdaqCM:HOTH) in a reverse merger transaction.

Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ

Hoth Therapeutics, Inc. Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Price target decreased to US$19.00

Hoth Therapeutics, Inc. announced that it expects to receive $10 million in funding

Hoth Therapeutics, Inc. Announces Board Changes

High number of new and inexperienced directors

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Reports Positive Biolexa Phase 1B Clinical Trial Results in Mild to Moderate Atopic Dermatitis

Hoth Therapeutics Announces 1:25 Reverse Stock Split to Regain Compliance

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Hoth Therapeutics, Inc. mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model

Hoth Therapeutics Gets 180 Grace Days by Nasdaq to Regain Compliance with Bid Price Rule

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Hoth Therapeutics, Inc, Announces HREC Approval in Australia for Next Phase of Trial of BioLexa for Patients with Atopic Dermatitis

Price target decreased to US$3.00

Hoth Therapeutics, Inc. Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort

Price target decreased to US$3.50

High number of new and inexperienced directors

Hoth Therapeutics, Inc. Announces Development Updates for Its Novel Cancer Therapeutic, HT-KIT

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference

Hoth Therapeutics, Inc. Announces Scientific Advisory Board Appointments

Hoth Therapeutics, Inc. Begins Dosing to Investigate the Effect of HT-ALZ on Memory, Anxiety, and Executive Function

Hoth Therapeutics, Inc. Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid ß in Alzheimer's Disease

Hoth Therapeutics, Inc Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis

Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way

Price target decreased to US$4.75

Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Hoth Therapeutics, Inc. Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial

Hoth Therapeutics, Inc. Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa

Price target decreased to US$7.25

Hoth Therapeutics, Inc. Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease

Hoth Therapeutics, Inc. Announces Positive Confirmatory Results from in Vivo Model of Ht-003 Assets as Potential Treatment Against Acne

Hoth Therapeutics extends agreement for experimental antibiotic

We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic

Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers

Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic

Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers

Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease

Hoth Therapeutics, Inc. announced that it expects to receive $15.000001 million in funding

Hoth Therapeutics, Inc. Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies

Hoth Therapeutics, Inc. Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment

Hoth Therapeutics, Inc. Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer Patients

Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs)

New 90-day high: US$3.04

Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv

Voltron Therapeutics, Inc. Initiates Additional Animal Testing of Self-Assembling Vaccine in Fight Against Covid-19

Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients

Hoth Therapeutics, Inc. Provides Operational Update on Novel Therapeutic Pipeline

Hoth provides pipeline and regulatory timeline update

Hoth Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment Research

Hoth Therapeutics Announces the Appointment of Mario E. Lacouture to its Scientific Advisory Board

Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 in Pursuit for Acne Treatment Indication